A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,080

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

August 31, 2031

Conditions
Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal NeoplasmsNeoplasm Metastasis
Interventions
DRUG

LY4170156

Administered IV

DRUG

Paclitaxel

Administered IV

DRUG

Topotecan

Administered IV

DRUG

Gemcitabine

Administered IV

DRUG

Pegylated liposomal doxorubicin

Administered IV

DRUG

MIRV

Administered IV

DRUG

Bevacizumab

Administered IV

DRUG

Carboplatin

Administered IV

Trial Locations (39)

10016

Laura and Isaac Perlmutter Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

11501

Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola

22010

Hospital Angeles, Tijuana

31207

Scientia Investigacion Clinica S.C., Chihuahua City

33136

University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami

33401

Florida Cancer Specialist- East, West Palm Beach

33901

Florida Cancer Specialist- South, Fort Myers

40207

Norton Women's and Children's Hospital, Louisville

45242

Oncology Hematology Care Inc, Cincinnati

50180

Centro Oncologico Estatal ISSEMyM ( COEI ), Toluca

60005

Illinois Cancer Specialists, Arlington Heights

60611

Northwestern Memorial Hospital, Chicago

71103

Trials 365, Shreveport

72424

Unidad Médica Onco-hematológica, Puebla City

76090

PanAmerican Clinical Research - Querétaro - Avenida Antea, Querétaro

77380

US Oncology, The Woodlands

78731

USO-Texas Oncology-Central/South Texas, Austin

85016

HonorHealth, Phoenix

93463

Sansum Clinic, Solvang

97130

Centro de Atención E Investigación Clínica En Oncología, Mérida

97401

USO - Oncology Associates of Oregon, P. C., Eugene

100142

Beijing Cancer hospital, Beijing

130021

The First Hospital of Jilin University, Changchun

310022

Zhejiang Cancer Hospital, Hangzhou

410008

Xiangya Hospital Central South University, Changsha

415003

The First People's Hospital of Changde City, Changde

430022

Wuhan Union Hospital, Wuhan

430030

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan

515031

Cancer Hospital of Shantou University Medical College, Shantou

530021

Guangxi Medical University Affiliated Tumor Hospital, Nanning

01605

University of Massachusetts Chan Medical School, Worcester

77598-4420

USO - Texas Oncology Gulf Coast, Webster

J1H 5N4

Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T, Sherbrooke

M5G 2M9

Princess Margaret Cancer Centre, Toronto

350-1298

Saitama Medical University International Medical Center, Hidaka

03100

CENEIT Oncologicos, Mexico City

Health Pharma Professional Research S.A. de C.V:, Mexico City

04700

COI Centro Oncologico Internacional S.A.P.I. de C.V., Mexico City

All Listed Sponsors
collaborator

GOG Foundation

NETWORK

collaborator

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

collaborator

Asia-Pacific Gynecologic Oncology Trials Group (APGOT)

UNKNOWN

lead

Eli Lilly and Company

INDUSTRY